Introduction {#s1}
============

Reciprocal balanced chromosomal translocations are recurrent and specific somatic aberrations in a wide variety of tumors, and are particularly associated with hematological malignancies [@pone.0056408-Mitelman1]. Sequence analysis of individual DNA breakpoints reveals fingerprints of different DNA recombination and repair mechanisms involved in chromosomal translocation, depending on the differentiation stage of the target cell at initiation. For example, chromosomal fusion sites of lymphoid malignancies are often linked to aberrant recombination activating gene (RAG)-mediated V(D)J recombination [@pone.0056408-Raghavan1]. In multiple myeloma, incorrect class switch recombination by activation-induced deaminase (AID) during secondary antibody diversification induces translocations within the immunoglobulin switch regions [@pone.0056408-Aplan1]. Chromosomal breakpoints in therapy-related acute lymphoblastic leukemia are clustered in proximity to topoisomerase II binding sites of the *MLL* gene [@pone.0056408-Greaves1], [@pone.0056408-Jung1]. By contrast, more immature leukemia cells show predominantly sequence-independent breakages [@pone.0056408-Tsai1].

Far fewer breakpoint DNA sequences have been deciphered from solid tumors to allow comparative analyses, although there is increasing evidence of recurrent chromosomal translocations in non-hematological tumors of both mesenchymal and epithelial origin [@pone.0056408-Xia1]--[@pone.0056408-Pierotti1]. One of the first solid tumors found to carry characteristic reciprocal chromosomal translocations was Ewing sarcoma [@pone.0056408-Sandberg1]. Ewing sarcoma family (ES) are the second most common solid bone and soft tissue malignancies in children, adolescents and young adults. ES are associated with chromosomal rearrangements that result in the fusion of the *EWS* gene with one gene of the *ETS* family of transcription factors. The most common translocation found in ES is t(11;22)(q24;q12), which fuses the *EWS* gene with the *FLI1* gene. More than 85% of Ewing sarcoma patients carry a *EWS-FLI1* fusion sequence. In 10% of cases, the *EWS* gene is fused to the *ERG* gene resulting in the t(21;22)(q22;q12) translocation [@pone.0056408-Riggi1]. Fusion transcript type does not appear to imply a prognostic impact with current treatment regimens [@pone.0056408-LeDeley1]. The frequency at which characteristic fusion genes were being identified led to the incorporation of molecular analysis, i.e., fluorescence *in situ* hybridization (FISH) or reverse transcription-PCR (RT-PCR), in the routine diagnostic workup for ES [@pone.0056408-Antonescu1], [@pone.0056408-Lazar1]. The large introns within the genomic breakpoint cluster regions (BCRs), however, mean that identification of genomic breakpoints is limited by the amplification range of conventional PCR, and detection of genomic fusion sites is not yet a routine diagnostic test. The BCR of the *EWS* gene spans a 5.7 kb region between exon 7 and exon 11, and the BCR of the *FLI1* gene extends from exon 4 to exon 9, encompassing 38.2 kb.

Using primers covering both of the BCRs a nested multiplex long-range PCR (MLR-PCR) assay was established for reliable identification of *EWS-FLI1* fusion sites. Unlike leukemia, where diagnostic material is easily accessible from blood or bone marrow, diagnostic samples of ES- are usually obtained by tumor biopsy and, therefore, the amount of diagnostic DNA for genomic studies is often very limited. Using the MLR-PCR assay described herein, it was possible to identify genomic *EWS-FLI1* fusion sequences from as little as 100 ng DNA from the tumors of all the pediatric and young adult Ewing-sarcoma patients investigated.

In addition to diagnostic aspects, sequencing of genomic fusion sites is a prerequisite for detailed breakpoint characterization to identify breakpoint initiation mechanisms, and could also provide complementary information about the cellular origin of ES-.

Materials and Methods {#s2}
=====================

Patients and Cell Lines {#s2a}
-----------------------

Genomic DNA was analyzed from t(11;22)(q24;q12) translocation-positive Ewing- sarcoma cell lines (n = 7), and 42 individuals (median age 14 years) whose cryopreserved tumor biopsies were sent to the Euro E:W:I:N:G:- 99 trial reference laboratory for pathological review and molecular diagnostics. Clinical and molecular parameters are summarized in [Table 1](#pone-0056408-t001){ref-type="table"}. Informed consent was obtained from all patients or their legal guardians, in accordance with the declaration of Helsinki.
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###### Patientś characteristics and breakpoint coordinates of tumor samples and cell lines.

![](pone.0056408.t001){#pone-0056408-t001-1}

  UPN         Age (y)   Sex   Localisation    RT - PCR    MLR - PCR    der22   der11    gains and losses                  
  ---------- --------- ----- -------------- ------------ ------------ ------- -------- ------------------ ------- ------- -------
                                                                                                                          
  1              4       F     Chest wall    ex7 - ex6    in8 - in5    21111   102511                                     
  2              3       F     Chest wall    ex7 - ex6    in8 - in5    22095   92502         90259         22454   −358    −2242
  3              7       M       Fibula      ex7 - ex6    in8 - in5    20804   101265        101204        20816    −11     −60
  4             12       M       Pelvis      ex7 - ex6    in7 - in5    19984   93467                                      
  5             21       M      Humerus      ex7 - ex6    in8 - in5    21707   92407                                      
  6             15       F       Pelvis      ex7 - ex6    in8 - in5    21206   98678                                      
  7             12       F     Lower leg     ex7 - ex6    in7 - in5    20171   106672                                     
  8             15       M      Humerus      ex7 - ex6    in7 - in5    19231   92652         92789         18978    254     138
  9              6       M       Fibula      ex7 - ex6    in7 - in5    20543   89407         89390         20547    −3      −16
  10            15       M       Fibula      ex7 - ex6    in7 - in5    19957   96301         96268         19979    −21     −32
  11            10       M       Femur       ex7 - ex6    in7 - in5    19581   95901         95903         19564    18       3
  12            13       M       Pelvis      ex7 - ex6    in8 - in5    20988   94580                                      
  13            10       M       Pelvis      ex7 - ex6    ex8 - in5    20663   98280         98274         20667    −3      −5
  14            15       F       Talus       ex7 - ex6    in7 - in5    19480   101933        101204        20816   −1335   −728
  15            16       M       Pelvis      ex7 - ex6    in7 - in5    19533   110315        110334        19538    −4      20
  16            16       F     Lower leg     ex7 - ex6    in8 - in5    20987   106613                                     
  17            18       M       Femur       ex7 - ex6    in7 - in5    20125   106653        106699        20055    71      47
  18            20       F       Pelvis      ex7 - ex6    ex8 - in5    20604   99064         99071         20611    −6       8
  19             8       M     Chest wall    ex7 - ex6    in8 - in5    20821   96410         96409         20848    −26      0
  20            21       M     Os sacrum     ex7 - ex6    in7 - in5    19651   103185                                     
  21            22       M         /         ex7 - ex6    in7 - in5    19144   110769        110770        19513   −368      2
  22            19       F       Fibula      ex7 - ex5    in8 - in4    21330   79881                                      
  23            30       M      Humerus      ex7 - ex6    in7 - in5    20127   98643         98651         20142    −14      9
  24            18       M       Tibia       ex7 - ex6    in7 - in5    19939   107245        107250        19938     2       6
  25             /       M         /         ex7 - ex6    in8 - in5    20860   93595                                      
  26            12       M      Humerus      ex7 - ex5    in7 - in4    19846   84791         84793         19851    −4       3
  27            13       M         /         ex10 - ex5   in10 - in4   24348   87199                                      
  28            14       M       Ilium       ex7 - ex6    in7 - in5    19743   92762                                      
  29             9       F       Pelvis      ex10 - ex8   in10 - in7   24275   113559        113559        24279    −3       1
  30            25       M      Skapula      ex7 - ex5    ex11 - in4   24534   81974                                      
  31             6       F       Tibia       ex7 - ex5    in7 - in4    19767   79357         79378         19750    18      22
  32            11       M       Femur       ex7 - ex6    in7 - in5    20506   96596         96872         20329    178     277
  33             4       M       Spine       ex7 - ex8    in7 - in7    20122   114396        114622        20119     4      227
  34            15       F       Femur       ex10 - ex5   in10 - in4   24229   87490         87543         24057    173     54
  35            16       M       Spine       ex7 - ex5    in8 - in4    21261   80293         79476         21555   −293    −816
  36             5       M       Tibia       ex7 - ex8    in8 - in5    21260   93863                                      
  37            16       M       Femur       ex10 - ex6   in10 - in5   24347   107895        107865        24342     6      −29
  38            17       M     Chest wall        /        in9 - in7    23584   113386                                     
  39             9       F       Fibula      ex7 - ex6    in8 - in5    20802   103255        103229        20802     1      −25
  40             9       M      Humerus          /        in7 - in4    20326   85673         86256         19661    666     584
  41            10       M      Skapula          /        in7 - in7    20029   115078        115070        20032    −2      −7
  42            15       M       Femur           /        in7 - in5    19996   111261        111251        19859    138     −9
  VH - 64                                    ex7 - ex5    In8 - In4    20874   82256         82445         20984   −109     190
  TC - 71                                    ex7 - ex6    In7 - In5    20429   96791         96795         20433    −3       5
  RD - ES                                    ex7 - ex5    In7 - In4    19680   85752         82518         19876   −195    −3233
  WE - 68                                    ex7 - ex6    In8 - In5    21418   92974                                      
  SKNMC                                      ex7 - ex6    In8 - In5    21511   100623                                     
  A673                                       ex7 - ex6    In7 - In5    20283   103693        103692        20284     0       0
  TC -- 32                                   ex7 - ex6    In8 - In5    21354   88394         88388         21259    96      −5

Cell lines were cultured in RPMI medium supplemented with 10% fetal bovine serum, L-glutamine, and antibiotics at 37°C in 5% CO~2~ on collagen-coated flasks. DNA from cell lines and tumor tissues was isolated using a QIAamp® DNA Blood and Tissue Mini Kit (Qiagen GmbH, Hilden, Germany).

Detection and Analysis of Genomic *EWS-FLI1* Fusion Sites {#s2b}
---------------------------------------------------------

Genomic *EWS-FLI1* fusion sequences (derivative (der)22) were amplified by nested MLR-PCRs using 11 nested primer pairs covering both of the *EWS* gene and *FLI1* gene BCRs ([Figure 1A](#pone-0056408-g001){ref-type="fig"}). Due to the different BCR length of the *EWS* and *FLI1* genes, the average distance between primers was 500 bp and 3000 bp, respectively. In addition, an analogous primer set in the opposite direction was designed for the amplification of *FLI1-EWS* fusion sites (der11) ([Figure S1](#pone.0056408.s001){ref-type="supplementary-material"}). Primer sequences and positions are shown in [Table S1](#pone.0056408.s004){ref-type="supplementary-material"}.

![Genomic fusion site sequencing.\
(A) Genomic organization of the *EWS* and *FLI1* genes and corresponding breakpoint cluster regions (BCR). Nested primer sets for der22 are shown as double headed arrows. (B) Representative breakpoint sequencing workflow. Left: Gel electrophoresis of MLR-PCR products from two tumor samples in lane 1 and 2 (lane 3 negative control DNA; lane 4 ddH~2~O; lane 5 positive control DNA; M = DNA ladder). Center: Gel electrophoresis of single long-range PCR products from 1^st^ round MLR-PCR product of sample 1 (lane 1--11; lane 12 positive control) to identify *FLI1* and *EWS* primers next to the fusion sites and to reduce amplification product size for direct sequencing. Right: Sequencing of the shortest amplification product and alignment to *EWS* and *FLI1* reference sequences.](pone.0056408.g001){#pone-0056408-g001}

All PCRs were performed using the AccuPrime™ *Taq* DNA Polymerase System (Invitrogen, Karlsruhe, Germany) according to the manufacturer's instructions. For the first round, MLR-PCR 100 ng template DNA was combined with the most 5′ *EWS* sense primer and 11 antisense *FLI1* primers. If no specific amplification product was visible by gel electrophoresis, a second round MLR-PCR was carried out with corresponding internal primers and 1 µl of first round MLR-PCR product as template DNA ([Figure 1B](#pone-0056408-g001){ref-type="fig"} left side). To identify the *FLI1* primer positioned next to the fusion site and, therefore, responsible for product generation, a series of single LR-PCRs was set up with the most 5′ internal *EWS* sense primer, one of each internal antisense *FLI1* primers, and again, with first round MLR-PCR product as template DNA. Subsequently, the appropriate *FLI1* primer was used in a series of single LR-PCRs in combination with additional internal sense *EWS* primers to further reduce the size of the specific amplification product for direct sequencing on a Beckman Coulter CEQ 8800 Genetic Analysis System ([Figure 1B](#pone-0056408-g001){ref-type="fig"} middle, right side). Patient-specific breakpoints were confirmed by an independent PCR using specific primer sets next to the patient's fusion site and 10 ng original tumor DNA.

Statistical Breakpoint Analysis {#s2c}
-------------------------------

Patient-specific fusion sequences were aligned to the NCBI reference sequences of *EWS* (NC_000022.10) and *FLI1* (NC_000011.9) using VectorNTI® software for sequence editing and analysis. Breakpoint and primer positions are numbered according to their positions in the reference sequences, starting with number one for the first nucleotide.

Repeat elements in the *EWS*- and *FLI1*-BCR were identified with the RepeatMasker tool (<http://www.repeatmasker.org/>). A Chi-square test was used to test for significant colocalization of patient-specific fusion sites and repeat elements or recombination-related DNA sequence motifs.

Components of the free software environment R ([www.r-project.org](http://www.r-project.org)) were applied to Kernel density analysis. Bandwidth selection was performed according to Sheather and Jones [@pone.0056408-Sheather1]. Clusters were defined as regions in which the lower limit of the 95% confidence band, determined by a bootstrapping procedure, was higher than a density function resulting from simulations at randomly distributed pseudo-breakpoints [@pone.0056408-Segal1]. Both bootstrapping and simulations used 1000 permutations.

Results {#s3}
=======

Detection and Sequencing of Genomic *EWS-FLI1* Fusion Sites {#s3a}
-----------------------------------------------------------

A nested MLR-PCR assay was developed for detection of genomic *EWS-FLI1* and *FLI1-EWS* fusion sites from diagnostic tumor biopsy specimens. PCR conditions were optimized using DNA from seven *EWS-FLI1*-positive Ewing- sarcoma cell lines ([Table 1](#pone-0056408-t001){ref-type="table"}). Sensitivity of the MLR-PCR was determined by a series of 2-fold dilutions of *EWS-FLI1-*positive A673 Ewing- sarcoma cells in *EWS-FLI1*-negative HL-60 cells. With the initial multiplex PCR, the *EWS-FLI1* fusion gene was detectable up to a 1∶64 dilution, corresponding to a tumor cell proportion of 1.6%. A subsequent quantitative real-time PCR, applying individually designed fusion site-specific primer and probe sets, allowed breakpoint detection with a sensitivity of 10^−4^--10^−5^ (data not shown).

A major advantage of the assay is the requirement for a minimal amount of DNA (100 ng) as both of the *EWS* and *FLI1* BCRs are covered by one single initial multiplex PCR. The genomic *EWS-FLI1* fusion sites (der22) were successfully amplified from all seven cell lines and 42 tumor samples ([Table 1](#pone-0056408-t001){ref-type="table"}). The reciprocal genomic *FLI1-EWS* fusion sites (der11) were detected in 27/42 Ewing sarcoma patients and five out of seven cell lines (overall 65%). The lower detection rate of the reciprocal *FLI1-EWS* fusion site is in line with results from other recurrent chromosomal translocations and is attributable to large deletions or complex rearrangements on der11 [@pone.0056408-ZucmanRossi1]--[@pone.0056408-TurcCarel1].

Alignments of individual fusion sites to the reference sequences are shown in [Figure S2](#pone.0056408.s002){ref-type="supplementary-material"}. The breakpoint sequences were deposited in the NCBI GenBank (accession numbers JX266448 to JX266528).

Distribution of Genomic Breakpoints {#s3b}
-----------------------------------

Breakpoint distribution analysis of all 49 *EWS-FLI1* fusion sites revealed two cluster regions within the *EWS*-BCR. Forty-three of 49 breaks (88%) were located in a cluster region spanning from intron 7 to the 5′-region of intron 8; the remaining six breaks (12%) were positioned in a region spanning from intron 9 to exon 11, constituting a second cluster region ([Figure 2A](#pone-0056408-g002){ref-type="fig"}). Kernel density analysis confirmed this observation and showed a statistically significant overrepresentation of breakpoints within the cluster region at the 5′-region of the *ESW*-BCR ([Figure 2B](#pone-0056408-g002){ref-type="fig"}). Due to the low number of breakpoints in the second cluster at the 3′-region of the *EWS*-BCR no statistical significance was obtained by Kernel density analysis. By contrast, breakpoints in the *FLI1*-BCR were randomly distributed ([Figures 2A and 2B](#pone-0056408-g002){ref-type="fig"}). Localization of *EWS* breakpoints showed no significant correlation with the corresponding *FLI1* breakpoints ([Figure 2C](#pone-0056408-g002){ref-type="fig"}).

![Breakpoint distribution in the BCR of *EWS* and *FLl1*.\
(A) Vertical bars above or below the breakpoint regions indicate individual breakpoint positions of Ewing sarcoma patients. Black boxes represent exons, and gray boxes correspond to repeat elements. (B) Results of Kernel density analysis (dashed line = breakpoint density; gray line = lower limit of 95% confidence band determined by bootstrapping procedure; black line = 95% confidence interval of a density function resulting from simulations at randomly distributed pseudo-breakpoints). X-axes indicate the BCR nucleotide positions within the respective reference gene. (C) Scatterblot of gender-specific *EWS-FLI1* breakpoints. Circles represent female, and squares represent male subjects. (D) Number of microhomologies and filler nucleotides at *EWS-FLI1* (der22; black bar) and *FLI1-EWS* (der11; gray bar) fusion sites. Each bar on the x-axis represents one individual.](pone.0056408.g002){#pone-0056408-g002}

Patients with breakpoints in the smaller *EWS* cluster region revealed no differences with respect to age, gender ([Figure S3A](#pone.0056408.s003){ref-type="supplementary-material"}) and tumor localization. Similar results were obtained for the *FLI1*-BCR; no correlation between breakpoint localization and gender or age at time of diagnosis was observed ([Figure S3B](#pone.0056408.s003){ref-type="supplementary-material"}).

In 34/49 (69%) samples, genomic breakpoints within the *FLI1* gene resulted in an *EWS-FLI1* fusion transcript of *EWS* exons 1--7 fused to *FLI1* exons 6--9, representing Ewing sarcoma type 1. In seven out of 49 (14%), there was an *EWS-FLI1* fusion transcript of *EWS* exons 1--7 and *FLI1* exons 5--9, corresponding to Ewing sarcoma type 2. In 15 patients and four cell lines with genomic breakpoints located in *EWS* exon 8 or intron 8, exon 8 was spliced out at the transcriptional level ([Table 1](#pone-0056408-t001){ref-type="table"}). The splicing out of exon 8 is essential to form a functionally active *EWS-FLI1* fusion transcript with an intact reading frame [@pone.0056408-Zucman1]. The frequencies of the different chimeric *EWS-FLI1* fusion transcript types in this study are consistent with published data [@pone.0056408-Lin1].

Sequence Analysis of *EWS-FLI1* and *FLI1-EWS* Fusion Sites {#s3c}
-----------------------------------------------------------

Genomic fusion sites of der22 and der11 were analyzed for colocalization with the following repeat elements and recombination-related DNA sequence motifs: *Alu* repeats, topoisomerase II binding sites, translin binding sites, chi-like sequences, heptamer/nonamer recombination signals, palindromic sequences, hypervariable minisatellite core sequence, hypervariable minisatellite recombination sequence, DNA polymerase frameshift hotspots, CpG islands, human replication origin consensus sequence, and repeat sequences such as low complexity, SINE/MIR, DNA/hAT-Charlie, and LINE/L2 ([Table S2](#pone.0056408.s005){ref-type="supplementary-material"}). No deviation between the expected and observed breakpoint within the DNA sequence motifs and repeat elements of *EWS*- and *FLI1*-BCR was observed ([Table S2](#pone.0056408.s005){ref-type="supplementary-material"}).

Detailed sequence analysis of the 49 identified *EWS-FLI1* and 32 *FLI1-EWS* genomic fusion sites revealed clean transitions between the two contributing genes in 30 cases (37%), 37 fusion sites (46%) featured small microhomologies (\<17 bp), and another 14 breakpoints (17%) presented with filler nucleotides at the fusion sites (\<16 bp) ([Figure 2D](#pone-0056408-g002){ref-type="fig"}). Patient UPN 5 showed an extended inverted insertion of a *FLI1* gene segment between the 5′ to 3′ *EWS* and *FLI1* portion at the genomic breakpoint.

These findings are comparable to breakpoint structures observed in hematological malignancies. Immature leukemia cells in particular show predominantly sequence-independent breakage with small microhomologies or deletions at the fusion sites [@pone.0056408-Greaves1], [@pone.0056408-Tsai1].

Discussion {#s4}
==========

Chromosomal fusion of the *EWS* gene to one member of the *ETS* family of transcription factors is the genetic hallmark of ES-. Detection of the chromosomal translocation by FISH, or amplification of the resulting fusion transcripts by RT-PCR, has become a well-established diagnostic component for molecular confirmation of histopathological tumor classification. Chromosomal breakage and re-fusion, however, occur in large intronic parts of the respective genes. Although the large size of the BCRs complicates the amplification of the breakpoint-spanning site, identification of the individual intronic DNA fusion sequence may unravel additional information associated with mechanisms involved in the rearrangement formation.

DNA-based tumor diagnostics has general advantages and disadvantages. The chemical stability of DNA facilitates storage and transport of patient material, and in contrast to RT-PCR methods, enables the detection of fusion genes independent of their gene expression. As a complementary diagnostic tool, DNA-based minimal residual disease detection could improve the quantification of resting residual tumor cells from different specimens including bone marrow, peripheral blood stem cell collection products, and paraffin-embedded, fixed-tissue sections. Fusion of *EWS* to one of its partner genes is an early event in tumorigenesis and an essential oncogenic factor for maintaining the malignant transformation of ES- [@pone.0056408-Prieur1], [@pone.0056408-Takigami1]. In contrast to secondary genetic aberrations occurring during clonal evolution and contributing to the genetic heterogeneity within an individual ES- [@pone.0056408-Mackintosh1], the genomic fusion site remains a common and consistent molecular marker of tumor cells, unaffected by clonal selection from therapeutic intervention, and is currently evaluated as an additional tool for tumor cell quantification during treatment.

A major obstacle in quantifying DNA breakpoints in ES is the identification of the genomic *EWS-FLI1* fusion sequence, because of large intronic regions within the BCRs. A classical approach, using multiple single PCRs to cover the complete BCRs, requires large amounts of patient material. This aspect and its consequent limit on the availability of adequate material for additional molecular diagnostics are probably the main reasons why only very few studies on genomic *EWS-FLI1* fusion sequences are published, in contrast to numerous studies on *EWS*-*FLI1* transcripts and genomic breakpoints in fusion genes in diseases with more freely available material, e.g., acute leukemia [@pone.0056408-LeDeley1], [@pone.0056408-vanDoorninck1]. Two studies have identified the genomic fusion sequence in a total of eight individual cases of ES on the basis of transcript amplification, using primers specifically designed for the region of interest [@pone.0056408-Bhagirath1], [@pone.0056408-Obata1]. A larger cohort of 77 Ewing- sarcoma patients was analyzed by Zucman-Rossi et al. using 15 single PCRs, but no patient characteristics are available and primer sequences have not been made permanently available [@pone.0056408-ZucmanRossi1].

In the present study, to overcome the problem of high DNA consumption, a nested MLR-PCR assay was established for reliable amplification of genomic *EWS-FLI1* fusion sequences. Highly stringent primer selection and the use of advanced polymerases facilitated the development of a detection assay based on a single initial MLR-PCR. Thus, only minimal patient material is required to extract template DNA (100 ng), enabling the detection of tumor genomic fusion sequences from small tumor samples, e.g., fine needle biopsies. Using this assay *EWS-FLI1* fusion sequences were identified from all 42 pediatric and young adult ES patients investigated. In addition, an analogous primer set was designed for detection of the second most common fusion gene in ES, the *EWS-ERG* gene. The assay can be readily adapted to include rare fusion partner genes occurring in the remaining 2--5% of cases [@pone.0056408-Riggi1].

The patient-specific breakpoints are distributed in two subclusters within the *EWS*-BCR, and this is in line with results from the cohort studied by Zucman-Rossi et al. [@pone.0056408-ZucmanRossi1]. Despite searching for an extensive spectrum of sequence motifs and repeat elements, no DNA motif associated with either of the breakpoint clusters or with a significant subgroup of Ewing sarcoma was identified. However, small microhomologies and filler nucleotides at the fusion sites, as well as deletions or insertion of several nucleotides in the corresponding chromosomal derivatives (der22 and der11), resemble the characteristics of non-homologous end-joining (NHEJ) repair, and suggest that NHEJ repair is involved in translocation formation in ES [@pone.0056408-Rassool1].

A comparison of genomic breakpoint features of ES- with the far more extensively characterized breakpoints in leukemia and lymphoma reveals a number of similarities. In cells from hematological malignancy, different DNA double-strand break and repair mechanisms are associated with the lineage and differentiation stage of the cell population. Sequence-independent breakages as observed in ES- are also characteristic for immature lymphoid malignant cells [@pone.0056408-Tsai1]. This subtype of leukemia cells shows small microhomologies or non-template insertions, as well as small deletions and duplications at the chromosomal breakpoint regions, indicating that NHEJ repair is involved in breakpoint initiation [@pone.0056408-Greaves1], [@pone.0056408-Langer1]--[@pone.0056408-vonGoessel1].

This observation of reciprocal balanced translocations with an NHEJ repair signature indicates molecular genetic similarities to mesenchymal tumors. It further supports results from functional and molecular genetic studies characterizing ES- by global gene expression profiling, which propose that ES- has its cellular origin in early mesenchymal progenitors [@pone.0056408-Richter1], [@pone.0056408-Lin2].

In summary, in this study, genomic *EWS-FLI1* fusion sequences were identified in a cohort of pediatric and young adult Ewing sarcoma patients with a specifically designed MLR-PCR assay requiring only minimal patient DNA. Detailed characterization of the genomic fusion sites revealed similarities to fusion site characteristics identified in immature lymphoid leukemia cells, and suggests that NHEJ repair mechanisms are involved in breakpoint initiation.
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